China's Ongoing 'COVID Zero' Policies To Prompt More Domestic Deals?
Executive Summary
China biotechs appear increasingly interested in partnering with domestic counterparts amid signs the Chinese government's restrictive "COVID Zero" policies are likely to stay until well into 2023.
You may also be interested in...
Asia Deal Watch: Hansoh, TiumBio Join Forces On Endometriosis Drug In Greater China
Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback
Closed-Loop Inspections? Strict COVID Zero Policy Delays FDA's China Field Trips
Chinese biotechs are bracing for lengthy delays as the nation’s unwaveringly stringent restrictions continue to cause barriers to on-site inspections from the US FDA. Hard-hit domestic firms are proposing a "quarantine bubble" like that used during the Beijing Winter Olympics to put back on track the field checks necessary for obtaining biologics approvals.
Behind The First Inhaled COVID Vaccine: Chinese-Language CEO Podcast With CanSino’s Xuefeng Yu
After securing the first approval globally for an inhaled COVID-19 vaccine, Chinese biotech CanSino CEO Xuefeng Yu sat down with Scrip in this Chinese-language interview to share his views on vaccine development and market opportunities in China and elsewhere.